Publisher's Note: FiercePharmaAsia is now weekly

Starting this week, we’ll be changing the frequency of FiercePharmaAsia to a once-weekly report. Moving forward, you will receive your newsletter in your inbox once per week on Tuesdays.  Your next newsletter should hit your inbox on Tuesday, August 23rd.

We have a few other changes to the newsletter that we are looking forward to. We are moving up our deadline to get the news to you faster and more in line with your local time zone. We’ll also be covering Asia news across all of the publications so follow our coverage on the website and in our other Life Sciences publications.

As always, thank you for being a part of the FiercePharma community. Your feedback is always welcome so please reach out any time with questions, comments, or suggestions on how we can do better. Rebecca Willumson (email | Twitter)

Suggested Articles

After two months of “residential surveillance,” Fangliang Zhang has been officially arrested for suspected smuggling.

Samsung Biologics makes Lilly's COVID antibody drug, just as it disbands an AstraZeneca joint venture. AZ's ex-China R&D head launches new firm.

After a slow clinical development program, the companies have decided there's no commercial value to bringing their Rituxan biosimilar to the market.